Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Sponsored Research and Clinical Trial Agreements (Tables)

Sponsored Research and Clinical Trial Agreements (Tables)

6 Months Ended

Jun. 30, 2021

Schedule of Research and Development for Sponsored Research and Clinical Trial Agreements

In 2018, Aevitas entered into a Sponsored Research Agreement (“SRA”) with the Trustees of the University of Pennsylvania (“UPenn SRA”), as amended in July 2019, for certain continued research and development activities related to the development of adeno-associated virus (“AAV”) gene therapies in complement-mediated diseases. Also in 2018, Aevitas entered into an SRA with the University of Massachusetts (“UMass SRA”), as amended in January 2020, for certain continued research and development activities related to the development of AAV. For the three and six months ended June 30, 2021 and 2020, Aevitas recorded the following expense in connection with its sponsored research and clinical trial agreements:


	For the Three Months Ended June 30,				For the Six Months Ended June 30,
($ in thousands)	2021		2020		2021		2020
UMass SRA	$	24		—	$	272	$	—
UPenn SRA		—		—		—		281
Total	$	24	$	—	$	272	$	281

Mustang [Member]

Schedule of Research and Development for Sponsored Research and Clinical Trial Agreements

For the three and six months ended June 30, 2021 and 2020, Mustang recorded the following expense in research and development for sponsored research and clinical trial agreements:


	For the Three Months Ended June 30,				For the Six Months Ended June 30,
($ in thousands)	2021		2020		2021		2020
City of Hope National Medical Center	$	—	$	—	$	—	$	500
IL13Rα2 (MB-101)		279		234		793		326
CD123 (MB-102)		21		65		226		296
CS1 (MB-104)		197		770		372		770
HER2 (MB-103)		31		—		154		—
PSCA (MB-105)		(4)		—		46		—
Fred Hutchinson Cancer Research Center - CD20 (MB-106)		327		189		998		716
St. Jude Children's Research Hospital - XSCID (MB-107)		176		1,558		280		1,558
Mayo Clinic		233		—		233		—
Total	$	1,260	$	2,816	$	3,102	$	4,166

Oncogenuity [Member]

Schedule of Research and Development for Sponsored Research and Clinical Trial Agreements

Oncogenuity


	For the Three Months Ended June 30,				For the Six Months Ended June 30,
($ in thousands)	2021		2020		2021		2020
Columbia	$	187	$	125	$	375	$	125
Oxford		95		—		174		—
McCormick Labs		66		—		122		—
Total	$	348	$	125	$	671	$	125